集结发力！健康险高质量发展路线图曝光：条款、费率、数据全打通

Core Viewpoint - The health insurance industry is transitioning towards high-quality development, focusing on product upgrades, rate updates, data sharing, and comprehensive support from various associations and organizations [3][7][21]. Group 1: Health Insurance Development Focus - The health insurance sector is emphasizing comprehensive development across products, terms, rates, data, and funding [2][7]. - The insurance industry association has established model clauses for medical insurance and a list of drug payment guarantees [2][8]. - The actuary association is working on compiling net cost tables for medical insurance and affordable health insurance [12][14]. Group 2: Current Trends and Statistics - With advancements in medical technology, the average life expectancy in China has reached 79 years, with significant increases projected for insurance buyers [4]. - The commercial health insurance market has seen rapid growth, with an average annual compound growth rate exceeding 20% over the past decade, and over 11,000 medical insurance products currently available [5][9]. - By 2025, commercial health insurance is expected to provide approximately 14.7 billion yuan in compensation for innovative drugs, reflecting a compound annual growth rate of 70% [11]. Group 3: Data Sharing and Cost Analysis - The actuary association is advancing the compilation of net cost tables for commercial medical insurance and affordable health insurance, which will aid in better pricing and risk matching [13][14]. - The establishment of a national medical insurance information sharing service is underway, which will enhance data sharing across the healthcare sector [15][17]. Group 4: Investment in Health Industry - By 2025, insurance funds are projected to invest over 150 billion yuan in medical-related projects through debt and equity investment plans [18]. - The total balance of funds directed towards the healthcare sector has exceeded 250 billion yuan, covering various areas such as medical services, innovative drugs, and medical devices [19].